Compare WKC & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WKC | CAPR |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | N/A | N/A |
| Metric | WKC | CAPR |
|---|---|---|
| Price | $26.46 | $23.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $28.75 | ★ $41.38 |
| AVG Volume (30 Days) | 922.2K | ★ 1.3M |
| Earning Date | 02-19-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,648,100,000.00 | $11,130,509.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.13 | $16,329.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.71 | $4.30 |
| 52 Week High | $31.54 | $40.37 |
| Indicator | WKC | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 56.26 | 44.90 |
| Support Level | $25.84 | $23.52 |
| Resistance Level | $28.16 | $24.74 |
| Average True Range (ATR) | 0.83 | 1.58 |
| MACD | -0.03 | -0.76 |
| Stochastic Oscillator | 53.55 | 2.92 |
World Kinect Corp is an energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers. It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. The company operates in three reportable segments consisting of aviation, land, and marine. The company earns the majority of its revenue from the Aviation segment.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.